UniProt Q8NE63 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Cabozantinib | 100.0% | 0.0% | 92.73 | 0.751 |
| 2 | Sorafenib | 98.5% | 1.5% | 96.72 | 0.776 |
| 3 | Regorafenib | 98.0% | 2.0% | 95.99 | 0.719 |
| 4 | Pacritinib | 96.2% | 3.8% | 88.64 | 0.452 |
| 5 | Ripretinib | 95.3% | 4.7% | 92.95 | 0.674 |
| 6 | Dabrafenib | 81.9% | 18.1% | 94.74 | 0.633 |
| 7 | Gilteritinib | 81.8% | 18.2% | 88.97 | 0.506 |
| 8 | Ponatinib | 75.1% | 24.9% | 78.23 | 0.534 |
| 9 | Apatinib | 70.8% | 29.2% | 97.73 | 0.704 |
| 10 | Tivozanib | 70.7% | 29.3% | 92.42 | 0.673 |
| 11 | Defactinib | 68.9% | 31.1% | 92.68 | 0.450 |
| 12 | Osimertinib | 67.8% | 32.2% | 97.24 | 0.733 |
| 13 | Umbralisib | 67.0% | 33.0% | 98.74 | 0.670 |
| 14 | Bosutinib | 66.7% | 33.3% | 87.22 | 0.555 |
| 15 | Abemaciclib | 59.8% | 40.2% | 91.48 | 0.563 |
| 16 | Afatinib | 58.5% | 41.5% | 98.50 | 0.709 |
| 17 | Upadacitinib | 57.2% | 42.8% | 97.98 | 0.663 |
| 18 | Dacomitinib | 54.8% | 45.2% | 97.99 | 0.664 |
| 19 | Encorafenib | 54.2% | 45.8% | 98.50 | 0.755 |
| 20 | Quizartinib | 53.1% | 46.9% | 99.50 | 0.737 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.10
- Epithelial log2(TPM+1): 0.10
- Fold change: -0.00
- Status: No significant change
High-confidence drugs
- Sorafenib — inh 98.5% · KISS 52.19
- Regorafenib — inh 98.0% · KISS 49.43
- Cabozantinib — inh 100.0% · KISS 45.63
Selectivity landscape vs inhibition on HIPK4
Each point is one of the 92 approved drugs; color = inhibition % on HIPK4.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…